EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.84
Index: ASX300 | ALL-ORDS

EBOS Group distributes healthcare, pharmaceutical and animal-care products and provides related services across Australasia.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$17.88

17 Aug
2026

0.200

OPEN

$17.70

1.13%

HIGH

$17.89

130,669

LOW

$17.54

TARGET
$25.14 40.6% upside
Franking for last dividend paid out: 95%
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . HLS . IDX . M7T . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 109.7 122.6 xxx
DPS (cps) xxx 112.9 102.9 xxx
EPS Growth xxx - 22.4% 11.7% xxx
DPS Growth xxx N/A - 8.8% xxx
PE Ratio xxx N/A 14.8 xxx
Dividend Yield xxx N/A 5.7% xxx
Div Pay Ratio(%) xxx 102.9% 84.0% xxx

Dividend yield today if purchased 3 years ago: 3.50%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 6.24

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 05/03 - ex-div 42.69c (franking 95%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx109.7
DPS All xxxxxxxxxxxxxxx112.9
Sales/Revenue xxxxxxxxxxxxxxx12,266.9 M
Book Value Per Share xxxxxxxxxxxxxxx1,348.0
Net Operating Cash Flow xxxxxxxxxxxxxxx418.5 M
Net Profit Margin xxxxxxxxxxxxxxx1.75 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx8.29 %
Return on Invested Capital xxxxxxxxxxxxxxx5.70 %
Return on Assets xxxxxxxxxxxxxxx3.07 %
Return on Equity xxxxxxxxxxxxxxx8.29 %
Return on Total Capital xxxxxxxxxxxxxxx10.08 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx156.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx82 M
Long Term Debt xxxxxxxxxxxxxxx1,540 M
Total Debt xxxxxxxxxxxxxxx1,622 M
Goodwill - Gross xxxxxxxxxxxxxxx2,245 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx184 M
Price To Book Value xxxxxxxxxxxxxxx2.64

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx146.0 M
Capex % of Sales xxxxxxxxxxxxxxx1.19 %
Cost of Goods Sold xxxxxxxxxxxxxxx11,346 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx497 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx95 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

04/05/2026

1

Buy

$28.00

56.60%

Ebos Group expects $610-620m in underlying EBITDA in FY26. The company has briefed investors and set out its medium-term strategic and financial initiatives.

Ord Minnett notes operating leverage is expected to accelerate earnings growth in the medium term with further upside from bolt-on M&A.

If the company can navigate the risks around community pharmacy competition and a transition in New Zealand for Chemist Warehouse, the broker envisages a material re-rating opportunity. Buy rating. Target edges down to $28 from $29.

FORECAST
Ord Minnett forecasts a full year FY26 dividend of 91.20 cents and EPS of 120.20 cents.
Ord Minnett forecasts a full year FY27 dividend of 85.40 cents and EPS of 122.00 cents.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

17/08/2026

2

Overweight

-

-

Jarden maintains an Overweight rating for Ebos Group with a NZ$30.50 target price ahead of its FY26 full-year financial release.

The broker expects the company to deliver FY26 EBITDA of $613m, falling within the guided $610m to $620m range while leverage remains stable at 2.2x.

The analyst focuses attention on Medical Technology and Community Pharmacy returns, observing nominal EBITDA growth and a 6.4% return on capital employed in FY25 across the medical technology segment.

The broker's estimates model 6% group EBITDA expansion to $649m in FY27, supported by healthcare volume growth alongside fuel cost management and Community Service Obligation funding retention.

Higher depreciation, amortisation, and financing expenses are projected to drive further underlying net profit contractions despite top-line organic growth.
Access Extra Coverage Research History >

EBO STOCK CHART

FNArena News on EBO

1
Australian Broker Call *Extra* Edition – Aug 17, 2026

Aug 17 2026 - Daily Market Reports
2
Treasure Chest: Beware Aussie Healthcare

Jul 17 2026 - Treasure Chest
3
Rudi’s View: Small Cap Favourites, AI & More

Jul 16 2026 - Rudi's View
4
Australian Broker Call *Extra* Edition – Jun 05, 2026

Jun 05 2026 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – May 04, 2026

May 04 2026 - Daily Market Reports

Latest Healthcare services News

1
Treasure Chest: Beware Aussie Healthcare

Jul 17 2026 - Treasure Chest
2
Major UK Win Highlights Alcidion’s Potential

May 27 2026 - Small Caps
3
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
4
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
5
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
6
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
7
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
8
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
9
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
10
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps